What medical indications are treated with Mavacamten?

Mavacamten (Miscellaneous Drug Preparations) is a pharmaceutical active substance. It is indicated for the treatment of Obstructive Hypertrophic Cardiomyopathy.

What is the recommended dosage for Mavacamten?

Standard adult dosage: Oral – 5 mg (once daily). Pediatric dosage: Not applicable – No approved pediatric dosage available. Always consult a registered physician for individualized dosage adjustments based on clinical assessment.

Is Mavacamten safe during pregnancy and breastfeeding?

Mavacamten is classified under Pregnancy Category "Not Assigned". Always consult your healthcare provider or OB/GYN before taking this medication during pregnancy or lactation.

What are the common side effects of Mavacamten?

**More than 10%:**; Dizziness (27%); 1-10%: Syncope (6%); Reduced LVEF (6%)

Dose.bd

Medicine Overview

Indication Guideline Dose Administration Side Effect Interaction Pregnancy Lactation Special Use Precaution Overdose Pharmacology Storage

Indication

Obstructive Hypertrophic Cardiomyopathy

Know Medicine, Follow Guideline

Details coming soon

Adult Dose

Clinical Information	Administration Information
Indication: Obstructive Hypertrophic Cardiomyopathy Age: Adult Condition: New York Heart Association class II-III	Dose: Oral – 5 mg Frequency: once daily Note: Starting dose. Initiation or up-titration in patients with left ventricular ejection fraction less than 55% not recommended.
Indication: Obstructive Hypertrophic Cardiomyopathy Age: Adult Condition: New York Heart Association class II-III	Dose: Oral – 2.5, 5, 10, or 15 mg Frequency: once daily Note: Allowable subsequent doses with titration. The maximum recommended dose is 15 mg once daily. Initiation or up-titration in patients with left ventricular ejection fraction less than 55% not recommended.

Child Dose

Clinical Information	Administration Information
Age: Child	Dose: Not applicable – No approved pediatric dosage available Note: No approved pediatric dosage available

Renal Dose

Clinical Information	Administration Information
Condition: Mild-to-moderate renal impairment (estimated glomerular filtration rate 30-89 mL/min/1.73 m2)	Dose: Unknown Note: No dosage adjustment required
Condition: Severe renal impairment and kidney failure, including patients on dialysis (estimated glomerular filtration rate less than 30 mL/min/1.73 m2)	Dose: Unknown Note: Dosage adjustment unknown

Administration

Administer mavacamten orally as a whole capsule once daily, with or without food, at approximately the same time each day. Do not break, open, or chew the capsules. The recommended starting dose is 5 mg, with subsequent titration to 2.5 mg, 5 mg, 10 mg, or 15 mg based on echocardiographic assessment of left ventricular ejection fraction (LVEF) and Valsalva LVOT gradient. Treatment initiation is not recommended in patients with LVEF less than 55%. Dose reduction or treatment interruption is required for patients initiating weak to moderate CYP2C19 inhibitors or moderate to strong CYP3A4 inhibitors, as well as those with intercurrent illness or LVEF reduction below 50%. Use in pediatric populations has not been established.

Side Effect

More than 10%:

Drug Interaction

Details coming soon

Disease Interaction

Details coming soon

Pregnancy

US FDA Note

BNF Recommendation Note

AU TGA Note

Lactation

US FDA Note

BNF Recommendation Note

AU TGA Note

Special Use

Renal Impairment Note

Hepatic Impairment Note

Pediatric & Geriatric Use Note

Precaution

Overdose

Pharmacology

Mechanism of Action

Pharmacokinetics

Pharmacodynamics

Storage

Details coming soon

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.